Introduction
Progressive macular hypomelanosis (PMH) was originally described in patients with FitzPatrick's skin type IV-VI from tropical and subtropical countries of the world (1, 2) . However, it has been found to have a world-wide distribution (2) . The precise aetiology and pathogenesis of PMH is yet to be fully understood. Although, Westerhof et al had observed that hair follicles within the lesions fluoresce coral red under wood lamp, but not inter-follicular or non-lesional skin (3) . This suggests the presence of a porphyrin producing organism in the follicle, of which they were able to isolate and identify as gram positive nonspore-forming anaerobic rod propronibacterium acnes (3, 4) . PMH is a common, often misdiagnosed dermatosis with a great cosmetic concern to the sufferer. Presentation is asymptomatic, ill-defined to discoid, non-scaly, symmetrical hypopigmented macules that sometimes coalesce into patches (4, 5) . The eruptions are often seen on the trunk, face and a satellite extension to the extremities, neck and buttocks. (4, 5, 6) . The clinical course of the lesions varies and some authors have asserted that the lesions tend to stabilize and undergo spontaneous regression over a period of 2-5years (2). While others stated that the normal course is one of a slow progression of the lesion overtime (6) . Some researchers have also reported more female preponderance in the ratio 3:1 when compared with male gender, but other studies did not support this observation (3, (5) (6) (7) (8) (9) . PMH can easily be distinguished from other hypopigmented disorder such as pityriasis alba, pityriasis versicolor, mycosis fungoides, vitiligo, leprosy and postinflammatory hypopigmentation both clinically and histologically (1, 5) . For example, it is not associated with initial erythema and scaling of pityriasis alba. In PMH, there is normal sensation, no prior history of inflammation, trauma, itching, pain or infection. Potassium hydroxide mounts of skin scrapings for Malassezia fungi is negative. Histologically, PMH is characterized by diminished pigment in the epidermis and a normal looking dermis (5, 6) . Presently, there is no agreeable first line treatment for Progressive Macular Hypomelanosis after trials of many treatment options (3) .
Phototherapy alone has been attempted for the treatment of PMH with variable outcomes. Psoralen ultraviolet A (PUVA) therapy was noticed to induce repigmentation after six (6) weeks of therapy but hypopigmented spots recurred in the same location within few weeks of stopping PUVA (10) . Also, an uncontrolled prospective study of narrowband ultraviolet B (NB-UVB) therapy was performed on 17 patients and repigmentation occurred by a gradual darkening of the lesions after some sessions of exposure. This was in contrast to repigmentation observed in vitiligo which occurred from discrete perifollicular islands (7, 11) . The
II. Materials And Methods
This was a retrospective study involving patients who were seen in our dermatology outpatients clinic from December 2013 to November 2016 in University of Abuja Teaching Hospital. Out of one thousand four hundred and four (1404) new patients seen, twenty three (23) of them were diagnosed as having progressive macular hypomelanosis, clinically and histologically where necessary. A questionnaire was designed to capture the following: bio data, body mass index (BMI), other family members with similar disease, clinical distribution of the lesion, duration of lesion, medication on or before presentation, minimal erythema dose (MED) at the commencement of narrow-band phototherapy (NB-UVB), number of sessions before noticeable repigmentation, percentage of repigmentation, relapse of repigmentation after stoppage of NB-UVB phototherapy, any adjunctive medication while on phototherapy and any noticeable side effect(s). Patients who had progressive macular hypomelanosis were exposed to narrow-band ultraviolet B (311nm) after explanation and consent duly signed for exposure. The NV-UVB (311nm) used was a Philip TL 01 (1000 series) ultraviolet therapy lamp unit with 8 bulbs by Solarc system incorporated (13) . TL/W/01 is a panel with eight (8) Acceptable distance or positioning at the commencement of treatment was 8inches-12inches (20-30cm) and energy delivered can vary due to time exposure (13, 14) . A minimal erythema dose (MED) was obtained for each patient as minimal energy delivered to cause mild redness on the skin of the patient after 24hours. However, because of the difficulty in obtaining MED in black skin an alternative which depends on skin type, previously described was used (14, 15, 16, 17) Almost all the patients were of the skin type V or VI, thus, their alternative MED were set at 1000 joules/cm 2 and above.Time of exposures or energy delivered was increasingly done at the rate of 20% to 25% of the previous energy exposed or with recourse to any observable side effect. Each patient had a chart where progress of their treatment, total energy delivered (TED) per session per week and side effect were duly documented. Other precautionary measures taken include wearing of opaque goggles during treatment and boxers for male patients during whole-body exposure. Progress of treatment was assessed based on skin colour restoration. Those who had no colour change scored 0-25%, minimal skin colour restoration were scored 26%-49%, moderate skin colour restoration were scored 50%-70% and maximum skin colouration were scored 76%-99% and complete repigmentation score was 100%.The information retrieved was into SPSS 20 and analysed accordingly. Frequency, means, standard deviation and correlations were some of the statistical tools used.
III. Result
A total number of 23 patients with PMB were recruited into the study. Mean age (standard deviation) was 28.0 (13.6) years and ranged -7-55 years. Male to female ratio was 3.6:1. Body surface area covered (in %) ranged 3-60% with a mean of 18.6%. Seven 7 (30.4%) declined treatment while 16 (69.9%) were treated with NB-UVB. Out of the 16, repigmentation was noticed in 13 (81.3%) cases. However, 4 cases of relapse were observed after 4-12 months of follow up. Up to 25%-90% repigmentation was noticed between 9 to ≥18 sessions. Mean (SD) MED was 1762.5 (552.4)joules/cm 2 , ranged 1000-2400joules/cm 2 . Number of sessionswas 6-49times with mean of 14.3 sessions.The duration of disease before presentation was 1.5-12years with a mean duration of 5.2years. Body surface area mostly affected was the face. While, 20 patients had hypopigmentation both on the face and other parts of the body, three had hypopigmentation on the face alone. Other parts of the body affected alongside the face include, the trunk, upper and lower limb, scalp, and buttocks. The part of the face mostly affected was the malar area and the nose (Table 1) . N =Total number of patients with PMH Face (Malar =4, nose=3, forehead =1, chin=1) There were 18 (78.3%)males and 5 (21.7%) females. Six 6 (26.1%) were aged ≤15years and 17 (73.9%) were older than 15years. Those who had primary education were 6 (26.1%), 5 (21.7%) and 12 (52.2%) had secondary and tertiary education respectively. The number of patients treated were 16 (69.6%) while 7 (30.4%) declined treatment. Eleven 11 (47.8%) of the patients had hypopigmentation on the face, trunk and upper limb, 4 (17.4%) of them had hypopigmentation on the face and trunk only while 3 (13.0%) of the patients had hypomelanosis on the face only (Table 1) . Mean BSA (%) involvement of the lesions in patients with ages ≤15years was 35.3%. This was significantly higher than was observed in patients older than15years (mean BSA of13.8) at p=0.004. There was a negative moderate correlation between age and percentage BSA. This indicates that as the ages increased, the body surface area involvedwith PMH is reduced and this relationship was statistically significant (p=0.031). 
Retrospective Analysis Of The Clinical Presentation

TED-Total Energy delivered
There was strong a correlation between number of session and minimal erythermal dose, total energy delivered, number of weeks on treatment and repigmentation (Table 3 ). These relationships were highly significant(p<0.05).The summary of Patients' treatment outcome is documented on table 4. Repigmentation was noticed between 9 th sessions and 18 th sessions of narrowband UVB phototherapy. Age-Patients'age as at the start of the study; TED-Total Energy Delivered 
Discussion
Progressive macular hypomelanosis is a rarely diagnosed disorder which poses challenges in relevant differential diagnosis of hypopigmentations.(1) Guillet etal had described the disorder as a primary, acquired, non-scaly macular hypopigmentation affecting mainly women from 18 years to 25 years of age (1) . Young women of West Indies extract and Caribbean immigrant population in France were seen having a widespread hypochromic macules on the trunk and less frequently on the abdomen (1, 2) .
In this study, there was predominance of male patients (78.3%) when compared with females. This is in agreement with Martinique et al who revealed that the disease is more widespread in men than women with mean age of 25 years (18) . Other studies have shown that progressive macular hypomelanosis can occur on any skin type but more frequently on Fitpatrick skin type IV-VI (2,3,5) and this was consistent with our findings. More than 90% of our patients had presentation of lesion on the face (mostly on the malar area, the nose, the forehead and the chin respectively). Other researchers had reported more of the lesions occurring on the trunk and the abdomen with rare involvement of the face and extremities (1, 2, 3, 6) . We found more percentage body surface area involvement in patients below 20 years when compared with older adults 30 years and above. About 12 (52.2%) of the patients who were 30 years and above have had the lesions present for more than 5 years without any sign of clinical improvement. This was in contrast with earlier observation by previous researchers (4, 12, 19) .
There have been variable outcomes of repigmentations in patients that have PMH who were exposed to narrowband ultraviolet B (NB-UVB). Duarte et al and Kim with his co researchers had reported more than 50% clinical improvement at the 16th session of NB-UVB (7, 20) . In the same study 39% had their lesion completely cured, while 26% had clinical improvement of their conditions up to 80-90% (20) . Our findings showed upto 50% of our patients on NB-UVB had about 60% of their skin colour restored by12 sessions of exposure while 
V. Conclusion
In conclusion, this study has helped to highlight the fact that PMH is an emerging cosmetic embarrassing disorder in our environment. It is more generalized when it appears in much younger age group as compared with older adult. NV-UVB is helpful when a reasonable number of sessions of exposure are done and maintenance dose needful to avoid relapse of repigmentation.
